Atea Pharmaceuticals, Inc. (AVIR)

3,8900 -0,0400 (-1,02%) Alla chiusura: 04:00PM EDT

Atea Pharmaceuticals, Inc.

225 Franklin Street
Suite 2100
Boston, MA 02110
United States
857 284 8891
https://ateapharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 75

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Jean-Pierre Sommadossi Ph.D.	Founder, Chairman, CEO & President	1,04M	N/D	1956
Ms. Andrea J. Corcoran J.D.	CFO, Executive VP of Legal & Secretary	712,48k	N/D	1962
Mr. Wayne Foster CPA	Executive VP of Finance & Chief Accounting Officer	580,46k	N/D	1969
Dr. Janet M. J. Hammond M.D., Ph.D.	Chief Development Officer	789,47k	N/D	1960
Dr. Maria Arantxa Horga M.D.	Chief Medical Officer	679,58k	N/D	1968
Ms. Jonae R. Barnes	Senior Vice President of Investor Relations & Corporate Communications	N/D	N/D	N/D
Mr. Ariyapadi N. Krishnaraj	Vice President of Marketing	N/D	N/D	N/D
Mr. Adel Moussa Ph.D.	Executive Vice President of Chemistry	N/D	N/D	N/D
Mr. Xiao-Jian Zhou Ph.D.	Executive Vice President of Early Stage Development	N/D	N/D	N/D
Mr. John F. Vavricka	Chief Commercial Officer	581,11k	N/D	1963

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Atea Pharmaceuticals, Inc. al 1 maggio 2024 è 9. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 10; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.